INFIQ (Infinity Pharmaceuticals) Scaled Net Operating Assets: -1.82 (As of Jun. 2023)


INFIQ Infinity Pharmaceuticals Inc INFIQ
16 GF Score
Price $0.00
View Full Analysis

What is Infinity Pharmaceuticals Scaled Net Operating Assets?

Infinity Pharmaceuticals INFIQ -99.00% 16 Scaled Net Operating Assets is -1.82 as of Jun. 2023. GuruFocus rates INFIQ with a GF Score™ of 16/100.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Infinity Pharmaceuticals's operating assets for the quarter that ended in Jun. 2023 was $3.49 Mil. Infinity Pharmaceuticals's operating liabilities for the quarter that ended in Jun. 2023 was $58.01 Mil. Infinity Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2023 was $29.95 Mil. Therefore, Infinity Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2023 was -1.82.

Infinity Pharmaceuticals Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Infinity Pharmaceuticals's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Infinity Pharmaceuticals Scaled Net Operating Assets Chart

Infinity Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.10 -0.54 -0.69 -1.47 -0.67

Infinity Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.78 -0.92 -1.09 -1.26 -1.82

INFIQ vs CLCS, RVLPQ, IVRN: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Infinity Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Infinity Pharmaceuticals Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infinity Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Infinity Pharmaceuticals's Scaled Net Operating Assets falls into.


INFIQ
16GF Score
Infinity Pharmaceuticals Inc INFIQ
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Infinity Pharmaceuticals Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Infinity Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2022 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2022 )
=(Operating Assets (A: Dec. 2022 )-Operating Liabilities (A: Dec. 2022 ))/Total Assets (A: Dec. 2021 )
=(3.838-60.285)/84.785
=-0.67

where

Operating Assets(A: Dec. 2022 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=42.151 - 38.313
=3.838

Operating Liabilities(A: Dec. 2022 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=61.202 - 0.324 - 0.593
=60.285

Infinity Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Jun. 2023 )
=(Operating Assets (Q: Jun. 2023 )-Operating Liabilities (Q: Jun. 2023 ))/Total Assets (Q: Mar. 2023 )
=(3.486-58.005)/29.951
=-1.82

where

Operating Assets(Q: Jun. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=21.232 - 17.746
=3.486

Operating Liabilities(Q: Jun. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=58.638 - 0 - 0.633
=58.005

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -1.82 mean?
Infinity Pharmaceuticals (INFIQ) has a Scaled Net Operating Assets of -1.82 as of Jun. 2023. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Infinity Pharmaceuticals and its competitors.
Is Infinity Pharmaceuticals' Scaled Net Operating Assets too high?
Infinity Pharmaceuticals' current Scaled Net Operating Assets is -1.82. Overall, Infinity Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Infinity Pharmaceuticals' Scaled Net Operating Assets compare to CLCS and RVLPQ?
Infinity Pharmaceuticals' Scaled Net Operating Assets of -1.82 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Infinity Pharmaceuticals and its competitors. Infinity Pharmaceuticals's current Scaled Net Operating Assets is -1.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Infinity Pharmaceuticals stock overvalued right now?
Infinity Pharmaceuticals (INFIQ) has a current Scaled Net Operating Assets of -1.82. The current Scaled Net Operating Assets is -1.82. Infinity Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Infinity Pharmaceuticals (INFIQ), the current Scaled Net Operating Assets is -1.82 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Infinity Pharmaceuticals Business Description

Address 1100 Massachusetts Avenue, Floor 4, Cambridge, MA, USA, 02138
Infinity Pharmaceuticals Inc is a clinical-stage biopharmaceutical company dedicated to developing novel medicines for people with cancer. It combines proven scientific expertise with a passion for developing novel small molecule drugs that target disease pathways for potential applications in oncology. It is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma, or PI3K-gamma.
16GF Score

Get the complete analysis for INFIQ

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price